drugset / Trial / NCT03383614
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
Phase 1
Completed
24 enrolled
Drugs for Neglected Diseases
Bayer · collabBill and Melinda Gates Foundation · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
Timeline
- Start
- 2017-11-14
- Primary completion
- 2018-10-15
- Completion
- 2018-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emodepside | Small molecule | 5 mg | Oral |
| Subject | Emodepside | Small molecule | 10 mg | Oral |